TEE
DRNA

Tibra Equities Europe’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Tibra Equities Europe’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-76,823
Closed -$734K – 241
2018
Q1 		$734K Buy
+76,823
New +$828K 0.13% 96

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tibra Equities Europe's DRNA Position: Q2 2018 in Review

Tibra Equities Europe sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2018, closing a stake of 76,823 shares — an estimated $734K sold.

Tibra Equities Europe first reported a position in DRNA in Q1 2018 and held it in 1 quarter. The position peaked at $734K in Q1 2018. 85 funds tracked by Wall St. Rank hold DRNA as of Q2 2018.

  • Tibra Equities Europe reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 76,823 Dicerna Pharmaceuticals, Inc. shares in Q2 2018, an estimated $734K.
  • Tibra Equities Europe first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Dicerna Pharmaceuticals, Inc. position peaked at $734K in Q1 2018.
  • 85 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2018.

Based on Tibra Equities Europe's 13F filing for Q2 2018, filed 10 Aug 2018.